Windsor Creek Advisors’s BridgeBio Pharma BBIO Stock Holding History

Windsor Creek Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-18,400	Closed	-$1.13M	–	173
2021 Q1	$1.13M	Buy	+18,400	New	+$1.2M	0.3%	80
2019 Q4	–	Sell	-13,000	Closed	-$279K	–	140
2019 Q3	$279K	Buy	+13,000	New	+$360K	0.07%	126

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Windsor Creek Advisors's BBIO Position: Q2 2021 in Review

Windsor Creek Advisors sold out of BridgeBio Pharma (BBIO) in Q2 2021, closing a stake of 18,400 shares — an estimated $1.13M sold.

Windsor Creek Advisors first reported a position in BBIO in Q3 2019 and held it in 2 quarters. The position peaked at $1.13M in Q1 2021. 200 funds tracked by Wall St. Rank hold BBIO as of Q2 2021.

Windsor Creek Advisors reported no remaining BridgeBio Pharma position as of Q2 2021 after selling out during the quarter.
Windsor Creek Advisors sold 18,400 BridgeBio Pharma shares in Q2 2021, an estimated $1.13M.
Windsor Creek Advisors first reported a position in BridgeBio Pharma in Q3 2019 and held it in 2 quarters.
Windsor Creek Advisors's BridgeBio Pharma position peaked at $1.13M in Q1 2021.
200 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2021.

Based on Windsor Creek Advisors's 13F filing for Q2 2021, filed 5 Aug 2021.